Leerink Partners Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $13
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has initiated coverage on Benitec Biopharma (NASDAQ:BNTC) with an Outperform rating and a price target of $13.
July 22, 2024 | 10:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Leerink Partners has initiated coverage on Benitec Biopharma with an Outperform rating and a price target of $13.
The initiation of coverage with an Outperform rating and a specific price target of $13 by a reputable analyst firm like Leerink Partners is likely to positively influence investor sentiment and drive short-term price appreciation for BNTC.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100